Clinical Trials /

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

NCT03257124

Description:

AZD9291 is an oral potent irreversible EGFR TKI selective for sensitizing EGFR mutation and T790M resistance mutation but sparing wild-type EGFR. Preclinical studies indicate that AZD9291 has significant exposure in the brain and activity against EGFR mutant brain metastasis. In addition, anti-tumor activities of AZD9291 in patients with advanced stage EGFR mutant NSCLC including patients with brain metastasis have been reported in an ongoing Phase I study. More recently, AZD9291 at a dose of 160mg also showed promising efficacy in heavily pre-treated patients with leptomeningeal disease from EGFR mutant NSCLC. Among 11 evaluable for response, 6 patients had LM imaging improvement and 3 out of 7 patients with abnormal neurological exam at baseline had symptomatic improvement. Compared to AZD9291, other 3rd generation EGFR TKIs, rociletinib or HM61713 has not been reported to be effective in most of CNS disease of NSCLC. Further, previous studies with AZD9291 showed anecdotal case series or undetermined for T790M mutation status, indicating more systematic study is warranted. Based on these data, the investigators are going to conduct phase II study of AZD9291 in NSCLC patients harboring T790M mutation who failed EGFR TKIs and brain and/or leptomeningeal metastasis.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS
  • Official Title: An Open Label, Multicenter, Phase II Study of AZD9291 in Non-small Cell Lung Cancer (NSCLC) Patients Harboring T790M Mutation Who Failed EGFR TKIs and With Brain and/or Leptomeningeal Metastasis

Clinical Trial IDs

  • ORG STUDY ID: 2016-09-058
  • NCT ID: NCT03257124

Conditions

  • Non-Small Cell Lung Cancer With EGFR T790M Mutation
  • With Brain and/or Leptomeningeal Metastasis
  • Failed Tyrosine Kinase Inhibitors

Interventions

DrugSynonymsArms
AZD9291AZD9291 in BM or LM cohort in T790M positive

Purpose

AZD9291 is an oral potent irreversible EGFR TKI selective for sensitizing EGFR mutation and T790M resistance mutation but sparing wild-type EGFR. Preclinical studies indicate that AZD9291 has significant exposure in the brain and activity against EGFR mutant brain metastasis. In addition, anti-tumor activities of AZD9291 in patients with advanced stage EGFR mutant NSCLC including patients with brain metastasis have been reported in an ongoing Phase I study. More recently, AZD9291 at a dose of 160mg also showed promising efficacy in heavily pre-treated patients with leptomeningeal disease from EGFR mutant NSCLC. Among 11 evaluable for response, 6 patients had LM imaging improvement and 3 out of 7 patients with abnormal neurological exam at baseline had symptomatic improvement. Compared to AZD9291, other 3rd generation EGFR TKIs, rociletinib or HM61713 has not been reported to be effective in most of CNS disease of NSCLC. Further, previous studies with AZD9291 showed anecdotal case series or undetermined for T790M mutation status, indicating more systematic study is warranted. Based on these data, the investigators are going to conduct phase II study of AZD9291 in NSCLC patients harboring T790M mutation who failed EGFR TKIs and brain and/or leptomeningeal metastasis.

Detailed Description

      1. Primary end points

             -  Overall response rate (ORR) in CNS -brain metastasis cohort

             -  Overall survival - Leptomeningeal with or without brain metastasis cohort

        2. Secondary end points

             -  Whole body disease control rate (DCR)

             -  Time to brain progression

             -  Progression free survival (PFS) in BM cohort

             -  Overall survival (OS)

             -  Adverse events (AEs)

             -  Exploratory analysis of EGFR mutation/T790M in tissue, plasma or cerebrospinal
                fluid (CSF)

        3. Treatment AZD9291 160mg po daily (1 cycle of 28 days)

        4. Total patient sample size Eligible patients will be divided into two cohorts, brain
           metastasis (BM) cohort and leptomeningeal metastasis (LM) with or without BM cohort. The
           two patient cohorts use different primary endpoints.

        5. BM cohort For the BM cohort, the primary outcome is overall response (CR+PR). Let P
           denote the overall response rate of AZD9291. From some preliminary data of response in
           the brain or leptomeningeal seeding with AZD 9291 in phase II AURA and BLOOM study, we
           hypothesized that H0:P= 10% and H1:P =30%. The BM cohort uses Simon's optimal two-stage
           design as follows.

           Stage 1: Treat n1 = 18 patients. If r1 = 2 or fewer patients respond, stop the BM cohort
           concluding that the study therapy is inefficacious. Otherwise, proceed to Stage 2.

           Stage 2: Treat additional n2 = 17 patients. If r = 6 or fewer patients respond among the
           cumulative n1 + n2 = 35 patients, then conclude that the study therapy is inefficacious.
           Otherwise, accept the study therapy for further investigation.

           This design has 1-sided alpha = 5% for P0 = 10% and power = 90% for P1 = 30%.
           Considering about 10%, of attrition due to ineligibility and dropout, a total of 40
           patients will be enrolled into the BM cohort.

        6. LM ± BM cohort

           The primary outcome of the LM ± BM cohort is overall survival (OS). Let μ denote the
           median OS of AZD9291 in this cohort. Based on some preliminary results (we need a
           reference), we hypothesize that H0: μ=3 months vs. H1: μ=5 months. Assuming an
           exponential OS distribution under H0, the investigators will conduct the 1-sample
           log-rank test. In this cohort, the investigators expect an accrual rate of 30 patients
           per year and about 10% of attrition, and will have an additional follow-up of 6 months
           after completion of accrual. Under these assumptions, we need N=40 patients (D=29
           deaths) for 90% of power by the 1-sample log-rank test with 1-sided alpha=5% (refer to
           Kwak and Jung 2013). The trial of this cohort is expected to take about 22 months (=16
           months for patient accrual + 6 months for additional follow-up).

        7. Statistical analysis plan

      The analysis is conducted separately for each cohort. OS, PFS, and time to brain progression
      will be summarized by Kaplan-Meier method. DCR and AEs will be summarized using contingency
      tables. Cohort specific analyses are conducted as follows.

      BM cohort

      Two-stage testing on ORR will be conducted as described in "Target number" section. If the
      final sample size is different from n1=18 or n1 + n2=35, then a 1-sided p-value will be
      calculated by Jung et al. (2006) and accept the experimental therapy if it is smaller than
      alpha = 5%. The ORR will be unbiasedly estimated by Jung and Kim (2004), and its confidence
      interval will be calculated by Jennison and Turnbull (1983).

      LM ± BM cohort

      The final analysis of this cohort will be conducted when D29 deaths are observed, which is
      expected to be about 22 months from the study open. The investigators will conduct a 1-sample
      log-rank test assuming the exponential OS distribution with a median of 3 months under H0.
    

Trial Arms

NameTypeDescriptionInterventions
AZD9291 in BM or LM cohort in T790M positiveExperimentalBrain metastasis cohort (BM cohort) Leptomeningeal metastasis cohort (LM cohort)
  • AZD9291

Eligibility Criteria

        Inclusion Criteria:

          -  EGFR activating mutant NSCLC patients who failed EGFR TKIs (gefitinib, erlotinib, or
             afatinib) and develop CNS disease (BM and/or LM) with T790M mutation either tissue or
             plasma. For patients with intracranial progression, prior radiation therapy is not
             mandatory. Extracranial progression is allowed.

          -  Patients who failed to 3rd generation EGFR TKIs (AZD9291 (80mg), Rociletinib, HM61713)
             and develop CNS progression but stable extracranial disease

          -  Age ≥18 years

          -  ECOG performance status of 0 to 2

          -  For BM, at least one measurable intracranial lesion as ≥ 10mm in the longest diameter
             by magnetic resonance imaging (MRI)

          -  For LM, at least one site of CNS leptomeningeal disease that can be assessed by MRI

          -  Adequate organ function as evidenced by the following;

               -  Absolute neutrophil count > 1.5 x 109/L;

               -  platelets > 100 x 109/L;

               -  total bilirubin ≤1.5 UNL;

               -  AST and/or ALT < 5 UNL;

               -  CCr ≥ 50mL/min.

          -  Female subjects must either be of non-reproductive potential

          -  Subject is willing and able to comply with the protocol

          -  Signed written informed consent

        Exclusion Criteria:

          -  Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a
             limited field of radiation for palliation within 1 week

          -  Any unresolved toxicities from prior therapy, greater than CTCAE grade 1

          -  Mean QT interval corrected for heart rate (QTc) ≥ 470 ms

          -  Uncontrolled systemic illness including uncontrolled hypertension, active bleeding, or
             active infection.

          -  Past medical history of interstitial lung disease, drug induced interstitial lung
             disease, radiation pneumonitis which required steroid treatment

          -  History of hypersensitivity to AZD9291

          -  Known intracranial haemorrahge which is unrelated to tumor Refractory nausea and
             vomiting
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Overall response rate (ORR) in CNS -brain metastasis cohort
Time Frame:December, 2019 (one-year follow-up from last patient -in)
Safety Issue:
Description:At least one visit response of CR (complete response) or PR (partial response) that is confirmed at least 4 weeks later by using RECIST 1.1 criteria

Secondary Outcome Measures

Measure:Whole body disease control rate (DCR)
Time Frame:December, 2019 (one-year follow-up from last patient -in)
Safety Issue:
Description:At least one visit response of CR (complete response), PR (partial response) or SD (stable disease) that is confirmed at least 4 weeks later by using RECIST 1.1 criteria.
Measure:Time to brain progression
Time Frame:December, 2019 (one-year follow-up from last patient -in)
Safety Issue:
Description:Time to brain progression is measured from the date of start of study to the date of progression of BM or LM.
Measure:Progression free survival (PFS) in BM cohort
Time Frame:December, 2019 (one-year follow-up from last patient -in)
Safety Issue:
Description:measured from the date of start of study to the date of disease progression or death from any cause.
Measure:Overall survival (OS)
Time Frame:December, 2019 (one-year follow-up from last patient -in)
Safety Issue:
Description:OS is measured from the date of start of study to the date of death from any cause
Measure:Adverse events (AEs)
Time Frame:December, 2019 (one-year follow-up from last patient -in)
Safety Issue:
Description:Adverse events will be measured by the CTCAE scale, version 4.
Measure:Exploratory analysis of EGFR mutation/T790M
Time Frame:December, 2019 (one-year follow-up from last patient -in)
Safety Issue:
Description:Exploratory analysis of EGFR mutation/T790M in tissue, plasma or cerebrospinal fluid (CSF)

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Samsung Medical Center

Last Updated